Medicare Part D drug pricing
April 8th, 2010
Reducing Medicare Part D drug prices requires careful tools, not simply the power to negotiate
Read the rest of this entry »
by
Kevin Outterson
|
Reducing Medicare Part D drug prices requires careful tools, not simply the power to negotiate
Read the rest of this entry »Posted in Biotech, Blog, Cost, Health Care Costs, Health Law, Pharma, Policy, Uncategorized | No Comments »
Copyright 2012 by Project HOPE: The People-to-People Health Foundation, Inc., eISSN 1544-5208. Health Affairs is pleased to offer Free Access for low-income countries, and is a signatory to the DC Principles for Free Access to Science. Health Affairs gratefully acknowledges the support of many funders.
